Cambridge, MA, April 22, 2014 – Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. These molecules are based on what the Company calls a general amyloid interaction motif, or GAIM, which recognizes a characteristic common to many toxic, misfolded proteins, not just one type of misfolded protein.